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ing factor in the analysis. However, 
recently published work has indicated 
no statistically signiﬁ  cant differences 
in the verotoxin proteins encoded by 
SF-O157 or non–SF-O157 strains or 
in their level of toxicity (9). Other 
virulence factors may contribute to in-
creased likelihood of HUS (4).
Our data suggest that infection 
with SF-O157 results in less severe 
colitis than does the more common 
non–SF-O157 infection. Less severe 
colitis could result in a lower risk for 
renal disease because less verotoxin 
would be translocated into the blood-
stream and bound to the kidneys. 
However, patients infected with SF-
O157 had anuria for longer periods 
and consequently had longer sessions 
of peritoneal and hemodialysis. Al-
though unknown bacterial or host in-
ﬂ  ammatory cytokines may contribute 
to enhanced disease progression, this 
observation is surprising and requires 
further investigation. Additional re-
search is needed to learn more about 
the virulence of SF-O157 strains and 
establish other host factors that con-
tribute to disease progression.
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Co-infection with 
Dengue Virus and 
Pandemic (H1N1) 
2009 Virus
To the Editor: Dengue is a mos-
quito-borne viral infection caused by 4 
related dengue viruses. Each of these 
viruses is capable of causing classic 
dengue fever or dengue hemorrhagic 
fever (DHF), but may also cause non-
speciﬁ  c febrile illnesses. As a result, 
dengue is often difﬁ  cult to diagnose 
clinically, especially because peak 
dengue season often coincides with 
that of other common febrile illnesses 
in tropical regions (1). Concurrent out-
breaks of inﬂ  uenza and dengue have 
been reported (2,3); this circumstance 
often leads to delayed recognition of 
the presence of one or other disease in 
the community.
In April 2009, a new strain of in-
ﬂ  uenza A virus known as pandemic 
(H1N1) 2009 virus was ﬁ  rst detected 
in the United States (4). Pandemic 
(H1N1) 2009 infections were ﬁ  rst 
detected in Puerto Rico in June 2009, 
and 59 deaths caused by the virus have 
been conﬁ  rmed to date. This inﬂ  uenza 
outbreak coincided with the typical 
dengue season in Puerto Rico, which 
led to diagnostic difﬁ  culties; both in-
fections disproportionately affected 
young persons, who often had similar, 
nonspeciﬁ  c symptoms.
We describe a case of laboratory-
conﬁ  rmed co-infection of dengue virus 
and pandemic (H1N1) 2009, and dis-
cuss the difﬁ  culties in distinguishing 
the 2 illnesses clinically. A 33-year-old 
woman (healthcare worker) in Ponce, 
Puerto Rico, sought treatment at an 
emergency department of a hospital 
in the southern part of the island with 
a 3-day history of febrile illness. Her 
symptoms began with throat irritation 
and earache; subsequently, cough, 
fever, and headache developed. She 
reported palpitations and generalized 
malaise but no other symptoms. The 
patient had no notable medical his-
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tory and denied taking any medicines 
apart from over-the-counter antipyret-
ics. She reported recent exposure to 
inﬂ  uenza at work and multiple recent 
mosquito bites. On physical examina-
tion, she had a temperature of 37°C, a 
heart rate of 91 bpm, and blood pres-
sure of 125/82 mm Hg. A tourniquet 
test result was positive. Her pharynx 
was erythematous without exudate, 
and she had rhinorrhea. She had no 
lymphadenopathy, rash, petechiae, or 
purpura. Several small, red papules, 
which the patient described as recent 
mosquito bites, were on her legs. The 
remainder of her examination showed 
no unusual ﬁ  ndings.
Laboratory studies showed a leu-
kocyte count of 5,300 cells/mm3 with 
a normal differential count, hemat-
ocrit 35.2%, and thrombocyte count 
of 239,000 cells/dL. Results of a chest 
radiograph was unremarkable. A na-
sopharyngeal swab was positive for 
inﬂ  uenza A virus by rapid test. Na-
sopharyngeal and serum samples were 
sent to the Centers for Disease Con-
trol and Prevention (Dengue Branch) 
for inﬂ  uenza and dengue testing. The 
patient was diagnosed with suspected 
pandemic (H1N1) 2009 infection and 
prescribed oseltamivir for 5 days. She 
returned for a follow-up visit 12 days 
after the onset of symptoms. She re-
ported having 2 more days of fever 
after her initial visit, but had no rash, 
petechiae, bleeding, or progression 
of respiratory symptoms. A second 
serum specimen was obtained during 
this visit.
The initial serum specimen was 
positive for dengue virus by serotype-
speciﬁ  c, singleplex, real-time reverse 
transcription–PCR (5). Her nasopha-
ryngeal specimen was positive by 
PCR for pandemic (H1N1) 2009 in-
ﬂ   uenza. The second, convalescent-
phase, serum specimen was negative 
for dengue immunoglobulin (Ig) M 
by IgM antibody–capture ELISA. The 
acute-phase and convalescent-phase 
samples were positive for IgG against 
dengue by ELISA (6), which indicated 
a secondary dengue infection. IgG ti-
ters exceeded the limits of the test for 
acute-phase and convalescent-phase 
samples, showing unusually elevated 
levels of IgG against dengue.
Distinguishing dengue and in-
ﬂ  uenza by clinical features alone can 
be difﬁ   cult. In an investigation of 
simultaneous dengue and inﬂ  uenza 
A outbreaks in Puerto Rico in 1977, 
similar percentages of persons with 
conﬁ  rmed dengue and conﬁ  rmed in-
ﬂ  uenza had classic dengue symptoms 
(2). Hemorrhagic manifestations, like 
those typically seen in DHF, have 
been reported with inﬂ  uenza A in pri-
or outbreaks (7,8) and with pandemic 
(H1N1) 2009 (Centers for Disease 
Control and Prevention, unpub. data). 
Previous inﬂ  uenza A outbreaks were 
initially believed to be outbreaks of 
DHF until careful laboratory investi-
gation proved otherwise (8). Our pa-
tient did not have the typical signs and 
symptoms of dengue (rash, eye pain, 
thrombocytopenia, arthralgia, petechi-
ae, or bleeding) that would differenti-
ate her condition from that of patients 
with other febrile illnesses. She did 
have a positive tourniquet test result 
and fever, which have been advocated 
as screening criteria for dengue infec-
tion in children, at the time of initial 
examination (9). Data for the speciﬁ  c-
ity and sensitivity of these criteria in 
adults are sparse, however, and some 
studies have shown a high incidence 
of positive tourniquet test results in 
patients with laboratory-conﬁ  rmed in-
ﬂ  uenza (7,8).
Our report demonstrates that co-
infection with dengue virus and pan-
demic (H1N1) 2009 can occur. Previ-
ous studies also have shown cases of 
probable co-infection with seasonal 
inﬂ  uenza and dengue (1,10), including 
1 fatal case (1). Because many den-
gue-endemic countries are experienc-
ing pandemic (H1N1) 2009 outbreaks, 
providers should consider the possi-
bility of viral co-infection, especially 
in severe cases, and should consider 
testing for both viruses.
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Bovine 
Tuberculosis in 
Buffaloes, 
Southern Africa
To the Editor: Emergence of bo-
vine tuberculosis (TB) in wildlife in 
southern Africa has implications not 
only for the conservation of the wild-
life species affected (1) but also for 
the health of humans and livestock 
living at the wildlife–livestock–hu-
man interface (2). Bovine TB in South 
Africa’s Kruger National Park was 
ﬁ  rst found in African buffaloes (Syn-
cerus caffer) in 1990 (3) and likely 
entered the park by cattle-to-buffalo 
transmission (4). Bovine TB infec-
tion has been spreading northward; 
in 2003, infection was conﬁ  rmed in a 
buffalo ≈60 km south of the Limpopo 
River. In 2005, a case was conﬁ  rmed 
only 6 km south of the river (D. Keet, 
unpub. data). In 2008, we isolated 
Mycobacterium bovis from African 
buffaloes in Zimbabwe.
During October 9–13, 2008, a to-
tal of 38 buffaloes from 4 herds were 
captured in Gonarezhou National 
Park (south of the Mabalauta area; 
22.0553°S, 31.4265°E). Blood sam-
ples were collected, sampled buffaloes 
were marked and released, and 3 adult 
females in each herd were equipped 
with radio collars. Buffalo tissue 
samples were collected, packaged, 
shipped, and handled at the Agricul-
tural Research Council–Onderstepoort 
Veterinary Institute according to proce-
dures recommended for controlling the 
spread of foot-and-mouth disease vi-
rus. Interferon-γ assay (5) results were 
positive for bovine TB for 4 (10.5%) 
buffaloes: 2 adult females and 1 young 
adult male from the same herd and 1 
adult female from another herd.
Four months later, a radio-col-
lared adult female and the young adult 
male, each of which had had positive 
interferon-γ assay results, were se-
dated and euthanized, and necropsies 
were performed in the ﬁ  eld. Samples 
for histopathologic examination and 
culture were collected from lymph 
nodes of the head and thorax. No acid-
fast organisms were detected, but the 
histologic ﬁ  ndings were strongly sug-
gestive of paucibacillary TB. M. bovis 
was isolated from the retropharyngeal 
lymph nodes of both buffaloes and 
from the bronchial and head lymph 
nodes of 1 of them. Both isolates were 
typed by analysis of variable number 
of tandem repeat (VNTR) sequences 
at 6 loci (exact tandem repeat A–F) (6) 
and compared with the VNTR proﬁ  les 
of ≈75 isolates from Kruger. All iso-
lates showed an identical VNTR pro-
ﬁ   le (7544*52.3), which suggests an 
epidemiologic link between the M. bo-
vis infections in the 2 parks. However, 
the exact tandem repeat loci had lower 
discriminatory power among Kruger 
isolates than did IS6110 restriction 
fragment length polymorphism typing 
(T. Hlokwe, unpub. data) (4). A typing 
regimen comprising different typing 
methods and markers will be useful 
for more accurately determining the 
genetic relationship between the iso-
lates from the 2 parks, Gonarezhou 
and Kruger.
The conﬁ   rmation of results for 
bovine TB–infected buffaloes in Zim-
babwe (Gonarezhou National Park) 
raises several questions regarding the 
transboundary spread of animal dis-
ease and has considerable manage-
ment implications for the Great Lim-
popo Transfrontier Conservation Area. 
The most likely scenario is buffalo-to-
buffalo contact across the boundary 
because the bovine TB cases reported 
here were located <45 km from the 
unfenced northern boundary of Kru-
ger National Park. Buffaloes, especial-
ly bulls and young heifers, frequently 
move from herd to herd and may 
contribute to the spread of M. bovis 
by mixing with unexposed herds (7). 
Although transboundary movements 
of buffaloes between Kruger and 
Gonarezhou have not been speciﬁ  cally 
documented, uncontrolled movements 
across the Limpopo River do occur 
(de Garine-Wichatitsky, unpub. data). 
However, >12 wild species in Kruger 
have now been found to be infected by 
bovine TB (2). Most of these species 
are probably not effective sources of 
M. bovis infection for buffaloes, but 
the disease epidemiology could rely 
on multihost reservoirs (8). Thus, a 
second scenario could be a buffalo-to–
unidentiﬁ   ed wild species–to-buffalo 
pathway, because species like greater 
kudu (Tragelaphus strepsiceros) ap-
pear to be able to maintain, spread, 
and even drive a bovine TB epidemic 
(4,9). A third scenario involves move-
ment of infected livestock across the 
boundaries of the 3 countries of the 
Great Limpopo Transfrontier Con-
servation Area, resulting in cattle-to-
buffalo transmission of bovine TB. As 
a last scenario, we cannot rule out the 
possibility that bovine TB infection of 
buffaloes has remained silent and un-
detected for decades in Zimbabwe.
The management implications of 
bovine TB in buffaloes in Gonarezhou 
National Park are considerable. Once 
bovine TB is established in a native 
free-ranging maintenance host, eradi-
cation is unlikely (2,10). Evaluation 
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